{{Rsnum
|rsid=11842874
|Gene=MCF2L
|Chromosome=13
|position=113040195
|Orientation=plus
|GMAF=0.1446
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=MCF2L
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 86.7 | 13.3 | 0.0
| HCB | 65.0 | 29.9 | 5.1
| JPT | 64.6 | 31.0 | 4.4
| YRI | 52.4 | 41.5 | 6.1
| ASW | 75.4 | 22.8 | 1.8
| CHB | 65.0 | 29.9 | 5.1
| CHD | 72.5 | 25.7 | 1.8
| GIH | 91.1 | 8.9 | 0.0
| LWK | 53.6 | 39.1 | 7.3
| MEX | 77.6 | 22.4 | 0.0
| MKK | 68.6 | 28.2 | 3.2
| TSI | 86.3 | 13.7 | 0.0
| HapMapRevision=28
}}[[rs11842874]] is a SNP in the MCF.2 cell line derived transforming sequence-like [[MCF2L]] gene on ch 13.

Based initially on a GWAS study of 3,000 patients of European ancestry with [[osteoarthritis]] and then subsequently replicated for a total of 19,000+ cases,  the [[rs11842874]](A) allele (major allele) was associated with increased risk, at an odds ratio of 1.17 (CI: 1.11–1.23, p = 2.1 × 10e?8). The authors note that [[MCF2L]] regulates a nerve growth factor (NGF), and treatment with a humanized monoclonal antibody against NGF is associated with reduction in pain and improvement in function for knee [[osteoarthritis]] patients.{{doi|10.1016/j.ajhg.2011.08.001}}

{{PMID Auto GWAS
|PMID=21871595
|Trait=None
|Title=A variant in MCF2L is associated with osteoarthritis.
|RiskAllele=A
|Pval=2E-8
|OR=1.1700
|ORtxt=[1.11-1.23]
|OA=1
}}

{{PMID Auto
|PMID=22615457
|Title=Genetic contribution to radiographic severity in osteoarthritis of the knee.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}